MLL genomic breakpoint distribution within the breakpoint cluster region in de novo leukemia in children.
OBJECTIVE
To assess translocation breakpoint distribution within the MLL genomic breakpoint cluster region (bcr), 40 cases of de novo leukemia in children were examined by karyotype and Southern blot analysis.


METHODS
Criteria for inclusion were karyotypic or molecular rearrangement of chromosome band 11q23. Of the 40 cases, 31 occurred in infants. Twenty cases were acute lymphoblastic leukemia (ALL), 17 were acute myeloid leukemia (AML), and 3 were biphenotypic.


RESULTS
Karyotype identified 27 cases with translocation of chromosome band 11q23 and 2 with abnormalities of band 11q13 but not 11q23. Southern blot analysis showed rearrangement within the MLL genomic bcr in 38 of the 40 cases. In these 38, additional probe-restriction digest combinations localized MLL genomic breakpoints to the 5' portion of the bcr in 14 cases and to the 3' portion in 18; material was insufficient for further localization to 5' or 3' within the bcr in 6 cases. In the two remaining cases, both with t(4;11)(q21;q23), one breakpoint mapped 5' of the bcr between intron 3 and exon 5, whereas the other breakpoint was neither within nor 5' of the MLL genomic bcr.


CONCLUSIONS
Suggested trends warranting investigation in more patients were breakpoint sites in the 3' bcr in AML and in patients older than 12 months. The distribution of MLL genomic breakpoints within the bcr in de novo leukemia in children is distinct from that in adults, where the breakpoints cluster in the 5' portion of the bcr.
Division of Oncology, The Children's Hospital of Philadelphia, Pennsylvania 19104-4318, USA.
C A
CA
Felix
M R
MR
Hosler
D J
DJ
Slater
R I
RI
Parker
M
M
Masterson
J A
JA
Whitlock
T R
TR
Rebbeck
P C
PC
Nowell
B J
BJ
Lange
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000367:Age Factors; D015139:Blotting, Southern; D002648:Child; D002675:Child, Preschool; D002880:Chromosomes, Human, Pair 11 / Q000235:genetics* / Q000648:ultrastructure; D004250:DNA Topoisomerases, Type II / Q000502:physiology; D004273:DNA, Neoplasm / Q000235:genetics; D004268:DNA-Binding Proteins / Q000235:genetics*; D004200:Diseases in Twins / Q000235:genetics; D005260:Female; D011495:Histone-Lysine N-Methyltransferase; D006801:Humans; D016130:Immunophenotyping; D007223:Infant; D007231:Infant, Newborn; D007621:Karyotyping; D007938:Leukemia / Q000145:classification / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D007951:Leukemia, Myeloid / Q000235:genetics / Q000401:mortality / Q000473:pathology; D008297:Male; D051788:Myeloid-Lymphoid Leukemia Protein; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000235:genetics / Q000401:mortality / Q000473:pathology; D011519:Proto-Oncogenes; D014157:Transcription Factors; D014178:Translocation, Genetic; D016896:Treatment Outcome
D004273:DNA, Neoplasm; D004268:DNA-Binding Proteins; C497422:KMT2A protein, human; D014157:Transcription Factors; D051788:Myeloid-Lymphoid Leukemia Protein; D011495:Histone-Lysine N-Methyltransferase; D004250:DNA Topoisomerases, Type II